Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Glaukos Corp Profil



BörsenkürzelGKOS

Name des UnternehmensGlaukos Corp

IPO-datumJun 25, 2015

CEOBurns (Thomas William)

Anzahl der mitarbeiter995

WertpapierartOrdinary Share

GeschäftsjahresendeJun 25

Addresse1 Glaukos Way

StadtALISO VIEJO

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl92656

Telefon19493679600

Websitehttps://www.glaukos.com

BörsenkürzelGKOS

IPO-datumJun 25, 2015

CEOBurns (Thomas William)

Führungskräfte von Glaukos Corp



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.70M

-0.24%

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.70M

-0.24%

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.70M

-0.24%

Mr. David F. Hoffmeister

Independent Director

86.97K

+19.41%

Mr. David F. Hoffmeister

Independent Director

86.97K

+19.41%

Mr. David F. Hoffmeister

Independent Director

86.97K

+19.41%

Mr. Mark J. Foley

Lead Independent Director

59.10K

+3.18%

Mr. Mark J. Foley

Lead Independent Director

59.10K

+3.18%

Mr. Mark J. Foley

Lead Independent Director

59.10K

+3.18%

Ms. Aimee S. Weisner, J.D.

Independent Director

51.57K

+3.64%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.70M

-0.24%

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.70M

-0.24%

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.70M

-0.24%

Mr. David F. Hoffmeister

Independent Director

86.97K

+19.41%

Mr. David F. Hoffmeister

Independent Director

86.97K

+19.41%

Mr. David F. Hoffmeister

Independent Director

86.97K

+19.41%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Glaukos Corp?



Die fünf größten Anteilseigner von Glaukos Corp sind: Mr. Thomas William Burns

Wie viele Institutionen halten Anteile an Glaukos Corp (GKOS)?



Mit Stand vom 2026Q1 halten 702 Institutionen Anteile an Glaukos Corp, mit einem Gesamtmarktwert von etwa 59.35M, was 101.04% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2784097.00 gestiegen.

Was ist die größte Einnahmequelle von Glaukos Corp?



Am 2026Q1 erzielte das Geschäft mit Glaucoma für Glaukos Corp den höchsten Umsatz in Höhe von 155.18M, was 83.61% des Gesamtumsatzes entspricht.